Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.
Zanini E, Forster-Gross N, Bachmann F, Brüngger A, McSheehy P, Litherland K, Burger K, Groner AC, Roceri M, Bury L, Stieger M, Willemsen-Seegers N, de Man J, Vu-Pham D, van Riel HWE, Zaman GJR, Buijsman RC, Kellenberger L, Lane HA. Zanini E, et al. Among authors: kellenberger l. Front Oncol. 2024 Aug 9;14:1447807. doi: 10.3389/fonc.2024.1447807. eCollection 2024. Front Oncol. 2024. PMID: 39184047 Free PMC article.
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
El Shemerly M, Zanini E, Lecoultre M, Walker PR, Kellenberger L, Lane HA, McSheehy PMJ. El Shemerly M, et al. Among authors: kellenberger l. Anticancer Drugs. 2023 Oct 1;34(9):1035-1045. doi: 10.1097/CAD.0000000000001480. Epub 2022 Dec 19. Anticancer Drugs. 2023. PMID: 36729099
The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo.
McSheehy PMJ, Forster-Gross N, El Shemerly M, Bachmann F, Roceri M, Hermann N, Spickermann J, Kellenberger L, Lane HA. McSheehy PMJ, et al. Among authors: kellenberger l. Anticancer Drugs. 2023 Apr 1;34(4):532-543. doi: 10.1097/CAD.0000000000001469. Epub 2022 Dec 2. Anticancer Drugs. 2023. PMID: 36729959
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Braun S, McSheehy P, Litherland K, McKernan P, Forster-Gross N, Bachmann F, El-Shemerly M, Dimova-Dobreva M, Polyakova I, Häckl M, Zhou P, Lane H, Kellenberger L, Engelhardt M. Braun S, et al. Among authors: kellenberger l. Expert Opin Investig Drugs. 2021 Nov;30(11):1071-1080. doi: 10.1080/13543784.2021.1995355. Epub 2021 Nov 9. Expert Opin Investig Drugs. 2021. PMID: 34698609 Review.
Extracellular matrix proteins and tumor angiogenesis.
Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM, Petrik J. Campbell NE, et al. Among authors: kellenberger l. J Oncol. 2010;2010:586905. doi: 10.1155/2010/586905. Epub 2010 Jun 29. J Oncol. 2010. PMID: 20671917 Free PMC article.
22 results